These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2275223)

  • 1. Pharmacokinetics of ranitidine in morbidly obese women.
    Davis RL; Quenzer RW; Bozigian HP; Warner CW
    DICP; 1990 Nov; 24(11):1040-3. PubMed ID: 2275223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery.
    Xu B; Zhou D; Ren L; Shulman S; Zhang X; Xiong M
    J Anesth; 2017 Dec; 31(6):813-820. PubMed ID: 28828532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ranitidine in a homogeneous population of intensive care unit patients during intermittent and continuous administration.
    Geus WP; Vinks AA; Lamers CB
    Scand J Gastroenterol Suppl; 1992; 194():55-8. PubMed ID: 1298048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration.
    Lopez ND; Phillips KM
    Pharmacotherapy; 2014 Sep; 34(9):e162-8. PubMed ID: 25074285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults.
    Pai MP
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4585-9. PubMed ID: 27185808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).
    Thorne-Humphrey LM; Goralski KB; Slayter KL; Hatchette TF; Johnston BL; McNeil SA;
    J Antimicrob Chemother; 2011 Sep; 66(9):2083-91. PubMed ID: 21700623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients.
    Garg DC; Baltodano N; Perez GO; Oster JR; Jallad NS; Weidler DJ
    Pharmacology; 1985; 31(4):189-93. PubMed ID: 4059323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin dosing in morbidly obese patients.
    Bauer LA; Black DJ; Lill JS
    Eur J Clin Pharmacol; 1998 Oct; 54(8):621-5. PubMed ID: 9860149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis.
    Comstock TJ; Sica DA; Harford A; Eshelman F
    Nephron; 1989; 52(1):15-9. PubMed ID: 2710266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluconazole serum concentrations and pharmacokinetics in an obese patient.
    Cohen LG; DiBiasio A; Lisco SJ; Hurford WE
    Pharmacotherapy; 1997; 17(5):1023-6. PubMed ID: 9324192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ranitidine in patients with renal failure.
    Garg DC; Baltodano N; Jallad NS; Perez G; Oster JR; Eshelman FN; Weidler DJ
    J Clin Pharmacol; 1986 Apr; 26(4):286-91. PubMed ID: 3700684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients.
    Kees MG; Weber S; Kees F; Horbach T
    J Antimicrob Chemother; 2011 Oct; 66(10):2330-5. PubMed ID: 21729931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranitidine kinetics in normal subjects.
    Chau NP; Zech PY; Pozet N; Hadj-Aissa A
    Clin Pharmacol Ther; 1982 Jun; 31(6):770-4. PubMed ID: 6280919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.
    Dvorchik BH; Damphousse D
    J Clin Pharmacol; 2005 Jan; 45(1):48-56. PubMed ID: 15601805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ranitidine in patients undergoing haemofiltration.
    Gladziwa U; Krishna DR; Klotz U; Ittel TH; Schunkert H; Glöckner WM; Mann H
    Eur J Clin Pharmacol; 1988; 35(4):427-30. PubMed ID: 3197752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin pharmacokinetics in normal and morbidly obese subjects.
    Blouin RA; Bauer LA; Miller DD; Record KE; Griffen WO
    Antimicrob Agents Chemother; 1982 Apr; 21(4):575-80. PubMed ID: 7081978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of gastric pH and volume in morbidly obese and lean patients undergoing elective surgery and effect of aspiration prophylaxis.
    Mahajan V; Hashmi J; Singh R; Samra T; Aneja S
    J Clin Anesth; 2015 Aug; 27(5):396-400. PubMed ID: 25935831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.
    Newman D; Scheetz MH; Adeyemi OA; Montevecchi M; Nicolau DP; Noskin GA; Postelnick MJ
    Ann Pharmacother; 2007 Oct; 41(10):1734-9. PubMed ID: 17726066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of sex differences in the pharmacokinetics of ranitidine in humans.
    Abad-Santos F; Carcas AJ; Guerra P; Govantes C; Montuenga C; Gómez E; Fernández A; Frias J
    J Clin Pharmacol; 1996 Aug; 36(8):748-51. PubMed ID: 8877680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.